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Letter to the Editor 
Diagnostic Genetics
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Dear Editor,
LAMA2-related muscular dystrophy can be classified into two 
clinical phenotypes: severe early-onset congenital muscular dys-
trophy and mild late-onset muscular dystrophy [1]. Several mild 
form muscular dystrophy cases have been diagnosed since Tan 
et al [2] reported the first case of late-onset LAMA2-related mus-
cular dystrophy, thus expanding the spectrum of this disease [3 
-6]. Late-onset LAMA2-related muscular dystrophy presents 
clinically as limb girdle muscular dystrophy patterns and is as-
sociated with the partial expression of laminin α2 [6]. Here, we 
describe a novel missense mutation (c.8725T>C/p.Cys2909Arg) 
in the LAMA2 in a patient diagnosed as having late-onset LAMA2-
related muscular dystrophy. This study was approved by the in-
stitutional research review board of the Catholic University of Ko-
rea, Incheon St. Mary’s Hospital. Written informed consent was 
obtained from the patient’s parents after they had been briefed 
about the study.
The proband was a 4-yr-old girl who visited our clinic for evalu-
ation because of a delay in motor milestone acquisition. Although 
there was no familial history of hereditary disorders, the patient’s 
younger sister had similar proximal lower extremity weakness 
symptoms. The patient exhibited gross motor developmental 
delay, but no difficulties with fine motor functions, and her cog-
nitive and speech skills corresponded with her age. Her serum 
creatine kinase concentration was 1,105 IU/L. Nerve conduc-
tion and needle electromyography studies did not reveal any de-
finitive myopathy or peripheral neuropathy findings. Following 
the first visit, the patient was referred to the genetic clinic. 
A gene panel test using next-generation sequencing for auto-
somal recessive limb girdle muscular dystrophy (30 genes: ANO5, 
CAPN3, CAV3, DAG1, DES, DNAJB6, DYSF, FHL1, FKRP, FKTN, 
GAA, GMPPB, HNRPDL, ITGA7, LIMS2, LMNA, MYOT, PLEC, 
POMGNT1, POMT1, POMT2, SGCA, SGCB, SGCD, SGCG, TCAP, 
TNPO3, TRAPPC11, TRIM32, and TTN), a multiplex ligation-
de pendent probe amplification test for Duchenne muscular dys-
trophy, and a dried blood spot test (lysosomal enzyme acid α-glu-
cosidase activity assay) for Pompe disease were performed; all 
test results were normal. The patient was subjected to further 
genetic testing using next-generation sequencing analyzing 4,813 
genes (approximately 62,000 exons) associated with several ge-
netic diseases in humans [7]. Genomic DNA was extracted from 
the peripheral blood of the patient as well as her parents and 
sister. The genomic DNA was enriched by using the TruSight 
One Sequencing Panel (Illumina, Inc., San Diego, CA, USA) [7]. 
This panel provides comprehensive coverage of approximately 
102 known protein-encoding genes involved in congenital my-
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opathy and muscular dystrophy. 
We found compound heterozygous variations in the patient’s 
LAMA2: a heterozygous nonsense variation in exon 49 (c.6955C 
>T/p.Arg2319*), previously reported as a pathogenic variation 
[8, 9], and a heterozygous missense variation in exon 62 (c.8725T 
>C/p.Cys2909Arg), which is a novel variation. The patient’s par-
ents were identified as heterozygous carriers for each variation, 
and the patient’s sister had the same variations as the patient. 
Each variation was confirmed by conventional Sanger sequenc-
ing. One of the compound heterozygous variations present in the 
LAMA2 of both siblings was a novel missense variation (c.8725T 
>C/p.Cys2909Arg). This variation has not been reported in con-
trol databases such as the 1,000 Genomes Project, Exome Vari-
ant Server, Exome Aggregation Consortium, and the dbSNP Da-
tabase, and has been predicted to be deleterious by several in 
silico analysis tools. This nucleotide variation is relatively conserv ed 
(GERP 5.22, phyloP7 0.991). Genetic analysis of the parents 
confirmed transconfiguration of the missense variant with the 
Fig. 1. Axial T2-weighted magnetic resonance images (A, the proband; B, the proband’s sister) showing diffuse high signal intensity in the 
bilateral periventricular and subcortical white matter.
A B
Fig. 2. Histologic examination of a muscle biopsy sample. (A) Hematoxylin and eosin (H-E) staining showing mild muscle fiber size varia-
tions, a few necrotic and regenerative muscle fibers, and endomysial edema (H-E stain, ×100). Immunohistochemical staining with the 
anti-laminin α2 antibody detected by 3,3´-diaminobenzidine (×200) showing decreased staining in the proband (B) compared with an age-
matched normal control subject (C).
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known pathogenic variant (c.6955C>T/p.Arg2319*). 
Brain magnetic resonance images (MRI) of the patient and 
her sister revealed diffuse symmetric high signal unmyelinated 
changes (Fig. 1). A biopsy of the patient’s left vastus lateralis 
muscle showed muscular dystrophic patterns. Immunohisto-
chemical staining was performed by using antibodies against 
the following proteins: the C-terminus of dystrophin, the rod do-
main of dystrophin, the N-terminus of dystrophin, α-sarcoglycan, 
β-sarcoglycan, γ-sarcoglycan, δ-sarcoglycan, dysferlin, α-dystro-
glycan, caveolin-3, and laminin α2 (whole laminin α2). The lam-
inin α2 staining in the patient was reduced compared with an 
age-matched normal control subject, whereas the staining of the 
other antibodies was non-specific (Fig. 2).
The proband and her sister showed similar clinical features, 
and the MRI findings of the two siblings and immunohistochem-
ical findings of the proband were compatible with LAMA2-re-
lated muscular dystrophy. The evidence presented above and 
the cosegregation of the variants in the affected sister, suggest 
that this missense variant is the pathogenic element, based on 
the American College of Medical Genetics and Genomics guide-
lines regarding the interpretation of sequence variations [10]. 
In conclusion, we present a patient diagnosed as having late-
onset LAMA2-related muscular dystrophy as a result of mutations 
in LAMA2 (including a novel mutation: c.8725T>C/p.Cys2909Arg) 
identified by next-generation sequencing. We suggest that this 
novel missense mutation (c.8725T>C/p.Cys2909Arg) is the path-
ogenic mechanism underlying the genotype-phenotype correla-
tion and annotation process. 
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